| Aug 2 |
BioNTech Q2 2024 Earnings Preview
|
| Jul 31 |
BioNTech SE's (NASDAQ:BNTX) largest shareholders are private equity firms with 43% ownership, insiders own 19%
|
| Jul 30 |
BioNTech posts mid-stage win for mRNA cancer drug with Regeneron’s Libtayo
|
| Jul 30 |
BioNTech's cancer drug meets primary endpoint in Phase 2 trial
|
| Jul 30 |
BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma
|
| Jul 24 |
Pfizer/ BioNTech win U.K. nod for JN.1-adjusted COVID-19 shot
|
| Jul 24 |
Triastek and BioNTech to develop 3D-printed RNA therapeutics
|
| Jul 22 |
BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024
|
| Jul 11 |
CureVac Provides Trial Dates for Patent Litigation Against Pfizer, BioNTech
|
| Jul 3 |
GSK Buys Full Rights To Investigational Covid-19 And Influenza Vaccines From CureVac For Around $1.5B
|
